Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19: Nanomix Wins BARDA Funding For Mobile Point-Of-Care Assay

Executive Summary

The US government’s Biomedical Advanced Research and Development Authority has awarded Nanomix up to $570,000 to develop a SARS-CoV-2 test for its portable, rapid Nanomix eLab analyzer.

You may also be interested in...



Luminex Will Be Acquired By DiaSorin For About $1.8Bn

The buyout will broaden DiaSorin’s positioning in the fast-growing molecular diagnostics space and expand Luminex’s foothold outside the US.

Sonica Health Develops Wearable For Early Warning Of COVID-19

The US government is helping Sonica develop ADAM, a patch monitor that tracks the user's breathing patterns and other physiologic signals to detect SARS-CoV-2 infections.

Abbott Rolls Out COVID-19 Antibody Test

Abbott has launched its first COVID-19 antibody test to help determine if a person has been previously infected with the virus. The diagnostics giant said it intends to ship a total of 4 million tests in April.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel